Patents
Treatment of muscular dystrophy with cord blood cells
Patent Number: 7,452,529Cord blood stem cells are currently approved only for hematopoietic reconstitution, however numerous experimental uses are being reported. Given that cord blood stem cells have been reported to possess pluripotent characteristics, a wide variety of new indications are being developed. For example, a...
Inventors: Brown, Jr.; Robert H. (Needham, MA), Finklestein; Seth P. (Needham, MA), Kraus; Morey (Jefferson, MA)
Assignee: Viacell, Inc. (Worchester, MA); The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Wednesday July 23rd, 2008
Method of expanding and differentiating cord blood cells by hyperthermic incubation
Patent Number: 7,452,662The stem cell compartment is part of a physiological system that responds to various stimuli. For example, during infections, the hematopoietic stem cells produce more granulocytes to fight off the sickness, or during periods of hypoxia (such as living on a mountain), they produce more erythrocytes. Inventors have used the physiological context of stem cells to come up with new...
Inventors: Dupuis; Nicolas (Quebec, CA), Proulx; Chantal (Sainte-Foy, CA)
Assignee: Hema-Quebec (Saint-Laurent, CA)
Date of First Priority Issue: Friday April 23rd, 2004
Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
Patent Number: 7,449,186Mobilization is currently performed using agents such as G-CSF clinically, experimentally agents such as parathyroid hormone are being investigated. The current patent teaches a new way to mobilize through blocking the interaction between hematopoietic stem cells and their stromal microenvironment using antibodies to...
Inventors: Masinovsky; Boris (Bellevue, WA), Gallatin; William Michael (Mercer Island, WA), Simmons; Paul J. (Seattle, WA)
Assignee: Fred Hutchinson Cancer Research Center (Seattle, WA)
Date of First Priority Issue: Thursday August 2nd, 1990
Methods and compositions for tissue regeneration
Patent Number: 7,449,333Numerous groups are working on means of accelerating wound healing, or wound healing with minimal fibrosis. For example, some have used mesenchymal stem cells to inhibit scar tissue formation, others have used gene therapy, such as transfection of HoxA3 and HoxD3. The current patent covers a cell preparation that can be used...
Inventors: Rolland; Eric (Divonne les bains, FR), Hunziker; Thomas (Oberhofen, CH), Mis; Beatrice (Lausanne, CH), Rinsch; Christopher (Lausanne, CH)
Assignee: DFB Pharmaceuticals, Inc. (San Antonio, TX)
Date of First Priority Issue: Friday September 6th, 2002
Compositions and methods for enrichment of neural stem cells using ceramide analogs
Patent Number: 7,445,931There are numerous ways to maintain embryonic stem cells in culture proliferating and not to lose their differentiation ability. For example, Novocell, Geron, and WARF have issued patents on various approaches to this problem. But perhaps equally, if not more, important is the question of...
Inventors: Condie; Brian G. (Athens, GA), Bieberich; Erhard (Augusta, GA)
Assignee: Bresagen, Inc. (Athens, GA); Medical College of Georgia Research Institute (Augusta, GA)
Date of First Priority Issue: Wednesday September 25th, 2002
Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
Patent Number: 7,446,100Stem cell mobilization is important commercially/medically from several angles. Firstly, donors of hematopoietic stem cells usually prefer to have their bone marrow resident stem cells "mobilized" so as to enter the blood and be collected from blood as opposed to having holes drilled in their iliac crest. Secondly, for some types of cancer, autologous hematopoietic stem...
Inventors: Pilarski; Linda M. (Spring Lake, CA)
Assignee: Orcrist Bio, Calgary Canada
Date of First Priority Issue: Tuesday April 2nd, 1996
Culturing human embryonic stem cells in medium containing pipecholic acid and gamma amino butyric acid
Patent Number: 7,442,548This patent covers new types of media useful for expansion of embryonic stem cells in absence of feeder cells or supernatant of other cells (conditioned media). The patent essentially covers the use of various concentrations of albumin, minerals, vitamins, amino acids, glucose, a fibroblast growth factor, gamma amino butyric acid, pipecholic acid, lithium, lipids, a transferrin or a...
Inventors: Thomson; James A. (Madison, WI), Ludwig; Tenneille (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Date of First Priority Issue: Wednesday September 8th, 2004
Combined effects of nutrients on proliferation of stem cells
Patent Number: 7,442,394Manipulation of the stem cell compartment using nutritional supplements offers a rapid way of commercially entering the area of regenerative medicine without having to undergo full-blown FDA clinical trials. Examples of such patents include #7,338,676 which teaches extracts of pinecones can induce stem cell differentiation into dendritic cells, patent #
Assignee: University of South Florida (Tampa, FL)
Date of First Priority Issue: Monday May 2nd, 2005
Method for enhancing engraftment of cells using mesenchymal progenitor cells
Patent Number: 7,442,390Stem cell transplantation in the form of cord blood, mobilized peripheral blood, or bone marrow, has saved many lives. One of the limiting factors of this procedure is graft versus host disease (GVHD). The other is poor engraftment. This is particularly important in situations...
Inventors: Seshi; Beerelli (Torrance, CA)
Assignee: University of South Florida (Tampa, FL)
Date of First Priority Issue: Monday June 5th, 2000
Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
Patent Number: 7,439,064There are problems with scalability of embryonic stem cells, as well as the fact that animal derived products are conventionally used during their culture. While fetal calf serum has previously been used, and is continued to be used in a lot of the stem cell clinical trials going on, there is always a desire to have "animal free" cells for clinical development. Companies such...
Inventors: Thomson; James A. (Madison, WI), Levenstein; Mark (Madison, WI)
Assignee: Wicell Research Institute, Inc. (Madison, WI)
Date of First Priority Issue: Thursday March 9th, 2000